207_Combined course Presentations

PCR Capecitabine/oxaliplatin pCR = 21% (10/48) capecitabine/irinotecan pCR = 10% (5/48) so the irinotecan arm was rejected But long-term follow-up showed • Numerically superior survival (4-year OS: 85% v 75%; P > .05) • The 4-year DFS 68% versus 62%.

Wong SJ et al. IJROBP 2015; 91(1):116-123